Alicia D. Zimmerman1, DVM; Robin E. Buterbaugh1, MS; John A. Schnackel2, DVM; Christopher C.L. Chase1,3, DVM, PhD, DACVM
1Rural Technologies, Inc., 1008 32nd Avenue, Brookings, SD 57006
2Fort Dodge Animal Health, 8138 Scenic Ridge Drive, Fort Collins, CO 80528
3Department of Veterinary Science, South Dakota State University, Brookings, SD 57007
A total of 22 commercial dairy calves were used to determine if vaccination with an adjuvanted, modifiedlive bovine viral diarrhea virus (BVDV) vaccine in the face of maternal antibody will protect calves from a virulent type 2 BVDV challenge seven months post-vaccination, following the loss of maternal antibody. Neonatal calves were obtained prior to consuming colostrum and were randomly divided into three groups. Group 1 calves were fed an antibody-free colostrum supplement within six hours of birth. Calves in Group 2 and Group 3 were fed pooled colostrum obtained from cows vaccinated eight weeks prior to calving with a commercial inactivated combination vaccine containing BVDV1 and BVDV2. Group 2 calves were vaccinated at approximately 4.5 weeks of age with a commercial modified-live virus combination vaccine containing BVDV1 and BVDV2. Calves in Groups 1 and 3 were sham vaccinated. Seven months after vaccination, when calves in Group 3 became seronegative to BVDV2, calves in all three groups were challenged intranasally with virulent BVDV2, strain 1373. Calves that received colostrum and were vaccinated had only mild or no clinical disease. Calves that did or did not receive colostrum and were sham vaccinated developed severe disease, with a mortality rate of 33-50%. In this study young calves vaccinated with an adjuvanted, modified-live virus vaccine in the face of maternal antibody were protected against challenge with a virulent strain of BVDV.
Keywords: bovine, vaccination, BVDV, maternal antibodies
Zimmerman AD, Buterbaugh RE, Schnackel JA, Chase CCL: Bov Pract 43:35-43, 2009.